ELCC 2025 | Dr. Benjamin Besse Discusses De-escalation in Lung Cancer Treatment: How Far Are We From the Goal?

ELCC 2025 | Dr. Benjamin Besse Discusses De-escalation in Lung Cancer Treatment: How Far Are We From the Goal?

At the 2025 European Lung Cancer Conference (ELCC), Professor Benjamin Besse from the Gustave Roussy Institute presented a report titled “Less is More: De-escalation Strategies in Patient Management and Clinical Trials.” He emphasized that while de-escalation strategies for drug treatments are still being actively explored, clinical applications face challenges, such as insufficient research funding.
Imaging, Heterogeneity & RCC Recurrence: Prof. Xiongjun Ye Shares Research Highlights at EAU25

Imaging, Heterogeneity & RCC Recurrence: Prof. Xiongjun Ye Shares Research Highlights at EAU25

At #EAU25, Professor Xiongjun Ye (叶雄俊) from Peking Union Medical College Hospital shared his team’s latest findings on MRI accuracy in renal tumor diagnosis, tumor heterogeneity in RCC, and strategies for managing postoperative recurrence. His group’s EAU-selected research explores how imaging limitations and intratumoral heterogeneity affect treatment outcomes—offering new perspectives for optimizing RCC care.
Advancing MIBC Treatment: ADCs, AI Models & Bladder-Sparing Strategies

Advancing MIBC Treatment: ADCs, AI Models & Bladder-Sparing Strategies

At #EAU25, we spoke with Prof. Haibin Chen and Prof. Ruiyi Zhang from Renji Hospital, Shanghai Jiao Tong University, who shared updates on their team's research in muscle-invasive bladder cancer (MIBC). They discussed a new study exploring ADC therapy for HER2+ MIBC, as well as progress in bladder-sparing treatment, ctDNA-based monitoring, and AI-driven molecular profiling for personalized treatment decisions.